256 related articles for article (PubMed ID: 25478223)
1. Effect of PAH specific therapy on pulmonary hemodynamics and six-minute walk distance in portopulmonary hypertension: a systematic review and meta-analysis.
Faisal M; Siddiqi F; Alkaddour A; Bajwa AA; Shujaat A
Pulm Med; 2014; 2014():528783. PubMed ID: 25478223
[TBL] [Abstract][Full Text] [Related]
2. Characteristic haemodynamic changes of cirrhosis may influence the diagnosis of portopulmonary hypertension.
Chiva T; Ripoll C; Sarnago F; Rincón D; Gómez-Camarero J; Galindo E; Catalina MV; Elizaga J; Bañares R
Liver Int; 2015 Feb; 35(2):353-61. PubMed ID: 24797536
[TBL] [Abstract][Full Text] [Related]
3. Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension.
Saxer S; Lichtblau M; Berlier C; Hasler ED; Schwarz EI; Ulrich S
Lung; 2019 Oct; 197(5):617-625. PubMed ID: 31263960
[TBL] [Abstract][Full Text] [Related]
4. Portopulmonary hypertension: a report from the US-based REVEAL Registry.
Krowka MJ; Miller DP; Barst RJ; Taichman D; Dweik RA; Badesch DB; McGoon MD
Chest; 2012 Apr; 141(4):906-915. PubMed ID: 21778257
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation.
Krowka MJ; Plevak DJ; Findlay JY; Rosen CB; Wiesner RH; Krom RA
Liver Transpl; 2000 Jul; 6(4):443-50. PubMed ID: 10915166
[TBL] [Abstract][Full Text] [Related]
6. The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan.
Takahashi Y; Yamamoto K; Sakao S; Takeuchi T; Suda R; Tanabe N; Tatsumi K
BMC Pulm Med; 2021 Mar; 21(1):89. PubMed ID: 33726742
[TBL] [Abstract][Full Text] [Related]
7. Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis.
Zhang R; Li T; Shao Y; Bai W; Wen X
Front Pharmacol; 2022; 13():991568. PubMed ID: 36467076
[No Abstract] [Full Text] [Related]
8. Right Heart Catheterization (RHC): A Comprehensive Review of Provocation Tests and Hepatic Hemodynamics in Patients With Pulmonary Hypertension (PH).
Gonzalez-Hermosillo LM; Cueto-Robledo G; Roldan-Valadez E; Graniel-Palafox LE; Garcia-Cesar M; Torres-Rojas MB; Romero-Martinez B; Castro-Escalante KY
Curr Probl Cardiol; 2022 Dec; 47(12):101351. PubMed ID: 35948196
[TBL] [Abstract][Full Text] [Related]
9. Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension.
Legros L; Chabanne C; Camus C; Fournet M; Houssel-Debry P; Latournerie M; Jezequel C; Rayar M; Boudjema K; Guyader D; Bardou-Jacquet E
Dig Liver Dis; 2017 Mar; 49(3):301-307. PubMed ID: 27840058
[TBL] [Abstract][Full Text] [Related]
10. Utility of right ventricular Tei-index for assessing disease severity and determining response to treatment in patients with pulmonary arterial hypertension.
Ogihara Y; Yamada N; Dohi K; Matsuda A; Tsuji A; Ota S; Ishikura K; Nakamura M; Ito M
J Cardiol; 2014 Feb; 63(2):149-53. PubMed ID: 24012334
[TBL] [Abstract][Full Text] [Related]
11. Current management approaches to portopulmonary hypertension.
Savale L; O'Callaghan DS; Magnier R; Le Pavec J; Hervé P; Jaïs X; Seferian A; Humbert M; Simonneau G; Sitbon O
Int J Clin Pract Suppl; 2011 Jan; (169):11-8. PubMed ID: 21176011
[TBL] [Abstract][Full Text] [Related]
12. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
[TBL] [Abstract][Full Text] [Related]
13. Portopulmonary hypertension: Results from a 10-year screening algorithm.
Krowka MJ; Swanson KL; Frantz RP; McGoon MD; Wiesner RH
Hepatology; 2006 Dec; 44(6):1502-10. PubMed ID: 17133488
[TBL] [Abstract][Full Text] [Related]
14. Portopulmonary hypertension.
Krowka MJ
Semin Respir Crit Care Med; 2012 Feb; 33(1):17-25. PubMed ID: 22447257
[TBL] [Abstract][Full Text] [Related]
15. Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis.
Minai OA; Santacruz JF; Alster JM; Budev MM; McCarthy K
Respir Med; 2012 Nov; 106(11):1613-21. PubMed ID: 22902266
[TBL] [Abstract][Full Text] [Related]
16. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
Klinger JR; Oudiz RJ; Spence R; Despain D; Dufton C
Am J Cardiol; 2011 Jul; 108(2):302-7. PubMed ID: 21545989
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Liver Transplantation in Treated Portopulmonary Hypertension Patients With a Mean Pulmonary Arterial Pressure ≥35 mm Hg.
DuBrock HM; Runo JR; Sadd CJ; Burger CD; Cartin-Ceba R; Rosen CB; Taner T; Nyberg SL; Heimbach JK; Findlay JY; Krowka MJ
Transplant Direct; 2020 Dec; 6(12):e630. PubMed ID: 33204828
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal membrane oxygenation rescue therapy in a case of portopulmonary hypertension during liver transplantation: a case report.
Stratta C; Lavezzo B; Ballaris MA; Panio A; Crucitti M; Andruetto P; Fanelli V; Grosso Marra W; Ranieri MV; Salizzoni M
Transplant Proc; 2013 Sep; 45(7):2774-5. PubMed ID: 24034045
[TBL] [Abstract][Full Text] [Related]
19. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension.
Provencher S; Herve P; Jais X; Lebrec D; Humbert M; Simonneau G; Sitbon O
Gastroenterology; 2006 Jan; 130(1):120-6. PubMed ID: 16401475
[TBL] [Abstract][Full Text] [Related]
20. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
Preston IR; Burger CD; Bartolome S; Safdar Z; Krowka M; Sood N; Ford HJ; Battarjee WF; Chakinala MM; Gomberg-Maitland M; Hill NS
J Heart Lung Transplant; 2020 May; 39(5):464-472. PubMed ID: 32008947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
